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aisunny2@yahoo.cAbstract The aim of this study was to prepare hydrogel disc implants containing cisplatin from
hydroxyethyl methacrylate (HEMA) and methyl methacrylate (MMA). To control drug release,
the monomers were cross-linked with ethyleneglycol dimethacrylate (EGDMA). Implants were
characterized by FTIR, DSC and SEM and evaluated for drug content, swelling, tensile strength,
in vitro and in vivo drug release, in vitro and in vivo biodegradation of the polymer and
histopathological studies. The in vitro results showed that increasing the concentration of either
MMA or EGDMA decreased drug release and prolonged the implant life. Histopathological
studies showed that the implants were histocompatible with surrounding tissue. Stability studies on
the optimized formulation showed it was stable over 90 days at 2573 1C. The implants can be used
to achieve controlled release of drug and attain effective treatment with reduced side effects.
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Table 1 Formulation chart of CDDP implants.
Ingredients FI FII FIII FIV FV
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Cancer continues to be a major contributor to high mortality
and the focus of continuing research to develop more effective
drugs and formulations. In recent years, considerable atten-
tion has been paid to the development of novel drug delivery
systems (NDDS) mainly because the cost and time required to
develop an NDDS for an existing drug is much less than to
develop a new drug. In the form of an NDDS, an existing drug
may have increased market value and extended patent life.
The implantable drug delivery system (IDDS) is an example
of an NDDS that has found therapeutic applications. The
major advantages of implants include controlled administra-
tion of a therapeutic dose at a desirable rate of delivery,
maintenance of drug concentration within an optimal ther-
apeutic range for prolonged duration of treatment, maximiza-
tion of the efﬁcacy–dose relationship, reduction of adverse
side effects, minimization of the need for frequent dosing and
enhancement of patient compliance. These advantages are
particularly relevant in cancer chemotherapy.
Cancer chemotherapy, whether given systemically or by regio-
nal perfusion of a particular organ or tissue, is impeded by the
lack of speciﬁcity of anticancer drugs for cancer cells. In fact,
chemotherapy is often curtailed due to systemic toxicity before
drug levels in the tumor reach therapeutic levels1,2. This problem
can be overcome through the use of IDDS made of various
polymers. An anticancer drug for which such an IDDS has
potential is cisplatin (cis-diamminedichloroplatinum(II), CDDP).
CDDP is a commonly used chemotherapeutic agent for
treatment of various cancers including testicular cancer,
ovarian cancer, lymphomas and gliomas. After both passive
and active cellular uptake, CDDP coordinates with the N7
atom of guanine in DNA to form an adduct and cause cellular
apoptosis. Chronic CDDP usage results in cellular accumula-
tion which induces resistance by several possible mechanisms.
To counteract this, clinical dosing of CDDP is generally
elevated to such an extent that it inevitably causes systemic
toxicity. Targeting CDDP to tumors through the use of an
IDDS has been shown to reduce toxicity and increase
activity3–8.
Previously studied CDDP implants made using polymethyl
methacrylate showed very slow and incomplete drug release
which can be attributed to the polymer’s hydrophobicity. In
the present work, cross-linking with the hydrophilic polymer
hydroxyethyl methacrylate (HEMA) was carried out with the
aim of improving the drug release proﬁle. Poly(2-hydroxyethyl
methacrylate-co-methyl methacrylate) hydrogel discs were
prepared containing CDDP and the characteristics of implants
made with different concentrations of each ingredient investi-
gated using DSC, FTIR and SEM. In addition, the in vitro
and in vivo release of CDDP and biodegradation of the
implants were examined.CDDP (mg) 10 10 10 10 10
2-Hydroxyethyl methacrylate
(%, w/v)
85 80 75 85 85
Methyl methacrylate (%, w/v) 15 20 25 15 15
Ethyleneglycol dimethacrylate
(%, w/v)
02 02 02 01 04
Ammonium persulphate (mg) 150 150 150 150 150
Sodium metabisulphite (mg) 100 100 100 100 100
Water q.s. q.s. q.s. q.s. q.s.2. Materials and methods
2.1. Materials
CDDP was kindly provided by Arora Mathew Ltd.. HEMA,
MMA and EGDMA were obtained from Sigma Aldrich USA.
Other chemicals were of analytical grade and used as received.2.2. Formulation of CDDP implants
CDDP, HEMA and MMA were added to 10 mL water with
stirring for over 2 min. Aqueous solutions of ammonium
persulphate (APS) and sodium metabisulphate (SMB) (as
initiators of polymerization) were added and the mixture stirred
for 1 min. Finally a solution of ethylene glycol dimethacrylate
(EGDMA) (as cross-linking agent) was added with stirring. The
composition of the various formulations is shown in Table 1.
The resulting solutions were cast on Petri dishes and allowed to
dry at 37 1C for 3 days. Polymerization was carried out using
different concentrations of MMA and HEMA (in FI, FII and
FIII) whilst keeping the concentration of EGDMA constant to
obtain the optimal blend ratio of the two monomers. After this,
the concentration of EGDMA was changed (in FIV and FV) to
study the effect of cross-linker on swelling and to determine the
concentration of cross-linking agent giving sustained release of
drug over a period of four weeks9–11. CDDP and the various
implant formulations were characterized by FTIR (Shimadzu)
using the KBr pellet method.
2.3. Swelling studies
Swelling characteristics of implants were determined by
immersing weighed discs (n¼3) in 25 mL phosphate buffer
(pH 7.4) at 37 1C. At speciﬁed times, samples were removed,
blotted dry and weighed. The swelling ratio (Qs) of test
samples was calculated using following the equation:
Qs ¼ ðWsWd Þ=Wd ð1Þ
whereWs is the weight of the swollen test sample andWd is the
initial weight of the test sample12,13.
2.4. Drug content, thickness and tensile strength
An amount of powdered disc equivalent to 10 mg drug was
placed in a 100 mL volumetric ﬂask, dissolved in 0.1 mol/L HCl
and analysed for CDDP by spectrophotometry at 302 nm.
Thickness of discs was measured using a digital screw gauge
taking the mean of three discs. Tensile strength of discs was
determined using a Hounse Field Universal testing machine14.
2.5. In vitro drug release
The in vitro release of CDDP from implants was investigated by
placing amounts equivalent to 20 mg drug in screw-capped vials
containing 20 mL phosphate buffered saline pH 7.4 (PBS). The
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shaken at 25 cycles/min. Samples were withdrawn at different
times up to 24 h, ﬁltered and analysed for drug by spectro-
photometry at 302 nm10.
2.6. In vivo drug release
Wister rats (n¼18, weight 300720 g) were used to study in
vivo release from formulations FIII, FIV and FV. An amount
of implant containing 20 mg CDDP was sterilized by gamma
irradiation under 32 kGy. For each formulation, 6 rats were
divided into 3 equal groups. The rats were anaesthetized by
intraperitoneal injection of pentobarbital sodium (50 mg/kg)
and a single incision (1–2 cm) made on their backs. Implants
were inserted at the site of incision after which the wound was
closed using standard surgical technique. After surgury, rats
were maintained under standard conditions with free access to
food and water. Drug release was estimated by excising
implants at predetermined times, extracting the drug with
PBS pH 7.4 and analysing by spectrophotometry at 301 nm.
The difference in the amount of the drug before and after
implantation was calculated to determine percentage release15.
2.7. Mathematical modelling of drug release data
The in vitro and in vivo release data were ﬁtted to the
Koresmeyer–Peppas equation (Eq. (2)) where Mt/MN is
the fractional solute released, ‘n’ is the time exponent, ‘k’ is
the release constant, and ‘t’ is the release time
Mt=M1 ¼ ktn ð2Þ
2.8. In vitro degradation
Implant discs 1 cm in diameter were placed in either 10 mL
phosphate buffer pH 7.4 containing lysozyme (1 mg/mL) (to
simulate saliva) or 1% saline and maintained at 37 1C. The
buffer was changed everyday and implants were removed after
7, 14, 21 and 28 days, washed with distilled water and
air dried for 72 h. The resulting dry weights were used to
determine the loss in weight16,17.
2.9. In vivo biodegradation
A total of 16 Wistar rats (weight 260–290 g) were divided into
four equal groups and used to test biodegradability ofFigure 1 FTIR spectra of CDDBimplants over 7, 14, 21 and 28 days. Rat were anaesthetized,
shaved at the surgical site, and a 1.5 cm incision made into
which implants (1 cm diameter) were inserted. At the speciﬁed
times, rats were again anaesthetized and implants removed.
Implants were sonicated in 1% aqueous Triton X-100 (Sigma,
USA) for 10 min, rinsed twice in distilled water and once in
70% ethanol solution before being dried in vacuum to
constant weight. Biodegradability was calculated as
Biodegradability¼ ðW1W2Þ=W1  100% ð3Þ
where W1 is the initial weight and W2 is the ﬁnal weight
18.2.10. Histopathology
The tissue surrounding implants was removed and preserved
in 10% buffered formalin. The study was carried out at the
Biochem Diagnostic Laboratories, Mysore, India19,20.2.11. Stability of optimized formulations
The optimized implant formulation (FV) was selected for a
stability studies. Implants were placed in screw-capped bottles
and maintained at either 2572 1C, 6075% RH or 4072 1C,
7575% RH for 90 days. Samples were collected after 0, 15,
30, 45 and 90 days and analysed for drug content.3. Results
3.1. FTIR
CDDP (A) and FV (B) were subjected to FTIR spectroscopic
analysis to investigate any interaction between the drug and
polymer. The FTIR spectra (Fig. 1) of pure drug and FV were
virtually superimposed, indicating that no interaction occurs
between CDDP and polymer.3.2. SEM
SEM was carried out to examine the surface morphology,
texture, porosity and cross-sectional area of implants. Fig. 2
shows the surface before and after swelling.(A) and formulation FV (B).
Figure 2 SEM photomicrographs of implant before (A) and after (B) swelling.
Figure 3 Swelling proﬁle of implant formulations FI–FV.
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Increasing MMA content decreased the hydrophilicity of the
polymer resulting in decreased swelling of FIII compared to
FI and FII. Swelling was also found to be more extensive in
FIV than in FI and FV due to the lower concentration of
cross-linking agent. Swelling proﬁles of the different formula-
tions are shown in Fig. 3.3.4. Drug content, tensile strength and thickness
Drug content was found to be75.0% of the nominal content.
Formulation FV showed the highest tensile strength and
greatest thickness whereas formulation FIV showed the least
tensile strength and lowest thickness. This is consistent with
the presence of the minimum and maximum concentrations of
cross-linking agent in FV and FIV, respectively. The values
are shown in Table 2.3.5. In vitro release
Release of CDDP from FIV showed 100% release after 18
days whereas FI, FII, FIII and FV showed 92% after 21 days,
100% after 27 days, 97% after 30 days and 89% after 30 days,
respectively (Fig. 4).
The release mechanism was studied by ﬁtting the data to
the Koresmeyer Peppas equation. The time exponent ‘n’
was in the range of 0.82–0.89 indicating anomalous behaviour(non-Fickian release, relaxation controlled). The values are
shown in Table 2.
3.6. In vivo release
The results of in vivo drug release are shown in Fig. 5. In vivo
drug release was faster than in vitro release from correspond-
ing formulations. This may be due to the inﬂuence of enzymes
or other in vivo factors. The release mechanism was evaluated
using the Koresmeyer Peppas equation. The ‘n’ values were
0.979 for FIII, 0.762 for FIV and 1.305 for FV indicating
anomalous behaviour (non-Fickian release, relaxation
controlled).
3.7. In vitro–in vivo biodegradation
The results of the in vitro and in vivo degradation of implants
are shown in Figs. 6 and 7. The results show that implants
degrade more extensively in lysozyme solution compared to
1% saline. FIV appears to undergo the most extensive surface
degradation.
3.8. Histopathology
Under normal conditions, tissue surrounding an implant is
composed of dense collagen ﬁbres, ﬁbroblasts with round to
oval nuclei and blood vessels. Sections showed muscle tissues,
red blood cells (RBCs) and ﬁbrous fatty tissue. After one
week, samples showed ﬁbrogenous and ﬁbrous muscle tissue
interspersed with chronic inﬂammatory cells and RBCs. After
two weeks, samples showed muscle tissue interspersed with
ﬁbrous collagenous tissue and mixed inﬂammatory cells. After
three weeks, samples showed muscle tissue with one of the foci
showing degeneration and a few mixed inﬂammatory cells.
After four weeks, samples showed muscle tissue with one of
the foci showing degeneration and inﬂammatory cells. The
images are shown in Fig. 8.
3.9. Stability studies
After storage of the FV hydrogel disc for 90 days at 25 1C/
65%RH, no change was observed in appearance and the
CDDP content was 9.770.09 mg. In contrast, after storage at
40 1C/75%RH, the drug content dropped to 7.570.05 mg at
the end of the study. Again there was no detectable change in
appearance.
Figure 4 In vitro drug release proﬁle of formulations FI–FV.
Figure 5 In vivo drug release proﬁles of formulations FIII, FIV
and FV.
Figure 6 Comparison between in vitro degradation of formula-
tions FI–FV in 1% lysozyme and 1% saline solution with the
in vivo degradation.
Figure 7 SEM micrograph of an implant after biodegradation.
Table 2 Drug content, tensile strength and thickness of implant formulations and curve ﬁtting of their in vitro–in vivo release
proﬁles.
Formulation Drug content (mg)n Tensile strength
(kg/mm2)n
Thickness (mm)n In vitro In vivo
n R2 n R2
FI 9.7270.12 5.470.6 0.6370.01 0.8630 0.9845 – –
FII 9.7070.24 4.370.8 0.6470.01 0.8431 0.9843 – –
FIII 9.7870.06 3.270.2 0.6170.01 0.8921 0.9938 0.9790 0.9984
FIV 9.6970.11 7.370.6 0.5370.01 0.8201 0.9862 0.7629 0.9995
FV 9.8770.03 2.570.4 0.68770.01 0.8590 0.9953 1.305 0.9791
nData are mean7standard deviation.
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SEM (Fig. 2) revealed the presence of many layers in the cross-
section of an implant before and after swelling. In contrast, the
surface of the dry hydrogel was microporous. It can be clearly
observed that cracks appear on the surface of implants after
swelling which are not visible before swelling. Swelling depends
upon the extent of cross-linking; at lower cross-linking density
the network is loose with greater hydrodynamic free volume
allowing the polymer chains to accommodate more solventmolecules resulting in greater swelling. Greater cross-linking
prevents penetration of solvent and thus reduces swelling.
Tensile strength of implants also decreased with decrease in
the extent of cross-linking.
In terms of in vitro drug release, it was found that release
depended on the extent of cross-linking and on the amount of
monomer present in the formulation. FIV was less cross-
linked and swelled rapidly resulting in higher release of drug
compared to FV which was more cross-linked and showed
lower release. Cross-linking between the monomer units
Figure 8 Histopathology of implanted tissue after 1 week (A) and 4 weeks (B).
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tion of dissolution media into the formulation and thereby
decrease swelling and drug release. Release of drug also
depends on the monomer concentration in the formulation.
Methyl methacrylate is a hydrophobic monomer which
decreases drug release with increasing concentration by
decreasing the hydrophilicity of the implant. It was found
that release from FIII was much lower than from FI and FII
due to its higher concentration of MMA.
The results indicate that the release of drug molecules from
a hydrogel based implant depends on the characteristics of the
polymer network such as the chemical structure of the
polymer, the network structure, pore size and extent of
crosslinking. The drug release rate decreased with increasing
cross-linking between the monomers. The results of the in vivo
biodegradation studies show that implants with lower cross-
linking show the greatest degradation compared to implants
with higher cross-linking.
Histopathological studies showed that inﬂammatory cells
(monocytes, lymphocytes, eosinophils and basophiles) were in
higher number after the ﬁrst and second weeks, but decreased
dramatically after three and four weeks. On this basis, it
appears that the implants are histocompatable with the
surrounding tissue.5. Conclusions
The objective of this study was to prepare and evaluate poly(2-
hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel
discs using CDDP as model drug. From the SEM study, it was
concluded that the surface of implants was porous. Based on
content uniformity, in vitro release, and in vitro-in vivo
degradation, FV was found to be the optimum formulation.
The in vitro results indicate increasing the MMA content leads
to slower drug release and prolonged implant life. The in vivo
results show that drug release is higher than in vitro which may
be attributed to in vivo enzyme activity. Histopathological
studies show that implants are histocompatible as there was a
decrease in the inﬂammatory cell count. Overall, this study
describes the development of a novel method of drug delivery
for cancer chemotherapy which can achieve controlled release
of drug at the cancer site and attain effective treatment with
reduced side effects.Acknowledgements
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